MX2020009836A - Oligonucleotidos antisentido de metaloproteinasa-1 de matriz. - Google Patents
Oligonucleotidos antisentido de metaloproteinasa-1 de matriz.Info
- Publication number
- MX2020009836A MX2020009836A MX2020009836A MX2020009836A MX2020009836A MX 2020009836 A MX2020009836 A MX 2020009836A MX 2020009836 A MX2020009836 A MX 2020009836A MX 2020009836 A MX2020009836 A MX 2020009836A MX 2020009836 A MX2020009836 A MX 2020009836A
- Authority
- MX
- Mexico
- Prior art keywords
- human mmp
- nucleic acid
- peptide nucleic
- antisense oligonucleotides
- matrix metalloproteinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describe un método para tratar enfermedades o afecciones asociadas con la transcripción génica de MMP-1 humano que implica la administración del derivado de ácido nucleico peptídico de conformidad con la reivindicación 1 a un sujeto. La presente invención proporciona el derivado de ácido nucleico peptídico de conformidad con la reivindicación 1, que se dirige al sitio de corte y empalme 5' del "exón 5" pre-ARNm de MMP-1 humano. Los derivados de ácido nucleico peptídico en la presente invención inducen en gran medida variantes de empalme del ARNm de MMP-1 humano en la célula y son muy útiles para tratar afecciones o enfermedades del envejecimiento de la piel asociadas con la proteína MMP-1 humana.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180057352 | 2018-05-18 | ||
PCT/KR2019/005994 WO2019221570A1 (en) | 2018-05-18 | 2019-05-03 | Matrix metalloproteinase-1 antisense oligonucleotides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020009836A true MX2020009836A (es) | 2021-01-08 |
Family
ID=68540475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020009836A MX2020009836A (es) | 2018-05-18 | 2019-05-03 | Oligonucleotidos antisentido de metaloproteinasa-1 de matriz. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210292369A1 (es) |
EP (1) | EP3794124A4 (es) |
JP (1) | JP7422406B2 (es) |
KR (1) | KR102194594B1 (es) |
CN (1) | CN112041447B (es) |
AR (1) | AR114533A1 (es) |
AU (1) | AU2019268955A1 (es) |
BR (1) | BR112020017892A2 (es) |
CA (1) | CA3091911A1 (es) |
MX (1) | MX2020009836A (es) |
SG (1) | SG11202008247WA (es) |
TW (1) | TWI832851B (es) |
WO (1) | WO2019221570A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102304280B1 (ko) | 2018-08-14 | 2021-09-23 | 올리패스 주식회사 | 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5719262A (en) * | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US6617422B1 (en) * | 1997-05-23 | 2003-09-09 | Peter Nielsen | Peptide nucleic acid monomers and oligomers |
US20030105044A1 (en) * | 2001-10-17 | 2003-06-05 | Isis Pharmaceuticals Inc. | Antisense modulation of matrix metalloproteinase 1 expression |
US20040241651A1 (en) * | 2000-04-07 | 2004-12-02 | Alexander Olek | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
DE10238298A1 (de) * | 2002-08-21 | 2004-03-04 | Beiersdorf Ag | Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen |
NZ546521A (en) * | 2003-09-29 | 2009-09-25 | Topigen Pharma Inc | Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
US7511025B2 (en) * | 2004-06-16 | 2009-03-31 | Trustees Of Dartmouth College | Compositions and methods for inhibiting the synthesis or expression of MMP-1 |
KR20090098710A (ko) * | 2008-03-14 | 2009-09-17 | 주식회사 씨티아이바이오 | 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체 |
KR20120073536A (ko) * | 2010-12-27 | 2012-07-05 | 주식회사 파나진 | 다중전하를 갖는 pna |
US20150240239A1 (en) * | 2014-02-27 | 2015-08-27 | Nugen Biosience (Taiwan) Co., Ltd. | Methods and pharmaceutical compositions for inhibiting matrix metalloproteinases 1 by interference ribonucleic acid |
CN107073294A (zh) * | 2014-09-05 | 2017-08-18 | 阿克赛医药公司 | 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法 |
US20190345202A1 (en) * | 2016-08-08 | 2019-11-14 | Olipass Corporation | Androgen receptor antisense oligonucleotides |
EP3512870B1 (en) * | 2016-09-16 | 2022-08-03 | Olipass Corporation | Scn9a antisense oligonucleotides |
RU2753517C2 (ru) * | 2016-10-11 | 2021-08-17 | Олипасс Корпорейшн | Антисмысловые олигонуклеотиды к hif-1-альфа |
US20190337987A1 (en) * | 2016-12-30 | 2019-11-07 | Olipass Corporation | Exon skipping by peptide nucleic acid derivatives |
-
2019
- 2019-04-02 TW TW108111655A patent/TWI832851B/zh active
- 2019-05-03 MX MX2020009836A patent/MX2020009836A/es unknown
- 2019-05-03 SG SG11202008247WA patent/SG11202008247WA/en unknown
- 2019-05-03 JP JP2020564534A patent/JP7422406B2/ja active Active
- 2019-05-03 BR BR112020017892-6A patent/BR112020017892A2/pt unknown
- 2019-05-03 AU AU2019268955A patent/AU2019268955A1/en active Pending
- 2019-05-03 US US17/055,809 patent/US20210292369A1/en active Pending
- 2019-05-03 WO PCT/KR2019/005994 patent/WO2019221570A1/en active Application Filing
- 2019-05-03 EP EP19802852.4A patent/EP3794124A4/en active Pending
- 2019-05-03 CA CA3091911A patent/CA3091911A1/en active Pending
- 2019-05-03 CN CN201980026668.4A patent/CN112041447B/zh active Active
- 2019-05-10 KR KR1020190054681A patent/KR102194594B1/ko active IP Right Grant
- 2019-05-17 AR ARP190101321A patent/AR114533A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR102194594B1 (ko) | 2020-12-23 |
JP2021524236A (ja) | 2021-09-13 |
WO2019221570A1 (en) | 2019-11-21 |
EP3794124A4 (en) | 2022-08-10 |
CN112041447B (zh) | 2024-09-13 |
CA3091911A1 (en) | 2019-11-21 |
EP3794124A1 (en) | 2021-03-24 |
KR20190132220A (ko) | 2019-11-27 |
TW202002991A (zh) | 2020-01-16 |
JP7422406B2 (ja) | 2024-01-26 |
BR112020017892A2 (pt) | 2020-12-22 |
TWI832851B (zh) | 2024-02-21 |
CN112041447A (zh) | 2020-12-04 |
SG11202008247WA (en) | 2020-12-30 |
AR114533A1 (es) | 2020-09-16 |
AU2019268955A1 (en) | 2020-11-26 |
US20210292369A1 (en) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gupta et al. | miRNAs in Alzheimer disease–a therapeutic perspective | |
Silva et al. | miR‐29c improves skeletal muscle mass and function throughout myocyte proliferation and differentiation and by repressing atrophy‐related genes | |
Zanotti et al. | Opposing roles of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy | |
US20170326254A1 (en) | Efficient delivery of therapeutic molecules in vitro and in vivo | |
MX2020008581A (es) | Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos. | |
US9909125B2 (en) | Molecular targets for selective eradication of senescent cells | |
JP2022532078A (ja) | 皮膚及び創傷のための組成物並びにその使用の方法 | |
US20200299652A1 (en) | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders | |
ATE524547T1 (de) | Einzelsträngige oligonukleotide, welche komplementär zu repetitiven elementen sind, zur behandlung von dns-wiederholungen-instabilitäts- assoziierten erkrankungen | |
PH12021551135A1 (en) | Rna encoding a protein | |
US20230009009A1 (en) | Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease | |
US20220265856A1 (en) | Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia | |
Wang et al. | Activating transcription factor 3 promotes spinal cord regeneration of adult zebrafish | |
MX2019008445A (es) | Calmante de dolor scn9a antisentido. | |
AU2019382824A8 (en) | Method and means to deliver miRNA to target cells | |
MX2020007433A (es) | Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos. | |
Li | The role of MicroRNAs in vitiligo: Regulators and therapeutic targets | |
MX2020009836A (es) | Oligonucleotidos antisentido de metaloproteinasa-1 de matriz. | |
MX2021000998A (es) | Oligonucleotidos antisentido de acetil-coa carboxilasa2. | |
US20220243182A1 (en) | Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease | |
US20220401584A1 (en) | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome | |
WO2023235509A3 (en) | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | |
MX2023009151A (es) | Composiciones para el tratamiento de afecciones y enfermedades asociadas con la expresion de policistina. | |
PL1618195T3 (pl) | Sposób selektywnego hamowania ludzkiego genu N-myc w nowotworach z ekspresją N-myc przez antysensowne i sensowne kwasy peptydonukleinowe | |
MX2019007903A (es) | Oligonucleotidos antisentido de proteina asociada a sinaptosoma de 25 kda (snap25). |